Per aspera ad astra: application of Simplex QSAR approach in antiviral research.

This review explores the application of the Simplex representation of molecular structure (SiRMS) QSAR approach in antiviral research. We provide an introduction to and description of SiRMS, its application in antiviral research and future directions of development of the Simplex approach and the whole QSAR field. In the Simplex approach every molecule is represented as a system of different simplexes (tetratomic fragments with fixed composition, structure, chirality and symmetry). The main advantages of SiRMS are consideration of the different physical-chemical properties of atoms, high adequacy and good interpretability of models obtained and clear procedures for molecular design. The reliability of developed QSAR models as predictive virtual screening tools and their ability to serve as the basis of directed drug design was validated by subsequent synthetic and biological experiments. The SiRMS approach is realized as the complex of the computer program 'HiT QSAR', which is available on request.

[1]  Vladimir Poroikov,et al.  Chemical Similarity Assessment through Multilevel Neighborhoods of Atoms: Definition and Comparison with the Other Descriptors , 1999, J. Chem. Inf. Comput. Sci..

[2]  Gerhard Klebe,et al.  Use of 3D QSAR Models for Database Screening: A Feasibility Study , 2008, J. Chem. Inf. Model..

[3]  Anatoly G. Artemenko,et al.  Virtual Screening and Molecular Design Based on Hierarchical Qsar Technology , 2009, Recent Advances in QSAR Studies.

[4]  J. Sutherland,et al.  A comparison of methods for modeling quantitative structure-activity relationships. , 2004, Journal of medicinal chemistry.

[5]  A. Vedani,et al.  Multi-dimensional QSAR in drug research. Predicting binding affinities, toxicity and pharmacokinetic parameters. , 2000, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[6]  Nina Nikolova-Jeliazkova,et al.  QSAR Applicability Domain Estimation by Projection of the Training Set in Descriptor Space: A Review , 2005, Alternatives to laboratory animals : ATLA.

[7]  Humberto González-Díaz,et al.  Multi-target spectral moment: QSAR for antiviral drugs vs. different viral species. , 2009, Analytica chimica acta.

[8]  A S Galabov,et al.  In vitro inhibitory effects of dual combinations of picornavirus replication inhibitors. , 1999, Acta virologica.

[9]  F. Maurel,et al.  Docking and 3D-QSAR studies of BMS-806 analogs as HIV-1 gp120 entry inhibitors. , 2009, European journal of medicinal chemistry.

[10]  F. Hayden,et al.  In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses. , 2000, Antiviral research.

[11]  Artem Cherkasov,et al.  Can 'Bacterial-Metabolite-Likeness' Model Improve Odds of 'in Silico' Antibiotic Discovery? , 2006, J. Chem. Inf. Model..

[12]  Håvard Jenssen,et al.  Modelling of anti‐HSV activity of lactoferricin analogues using amino acid descriptors , 2005, Journal of peptide science : an official publication of the European Peptide Society.

[13]  William Shakespeare,et al.  The Tragedy of Hamlet, Prince of Denmark , 1985, Hamlet.

[14]  F. Ooms,et al.  Molecular modeling and computer aided drug design. Examples of their applications in medicinal chemistry. , 2000, Current medicinal chemistry.

[15]  D. Barnard,et al.  Current status of anti-picornavirus therapies. , 2006, Current pharmaceutical design.

[16]  N Bodor,et al.  Soft drug design: General principles and recent applications , 2000, Medicinal research reviews.

[17]  Alexander Tropsha,et al.  Recent Advances in Development, Validation, and Exploitation of QSAR Models , 2010, Burger's Medicinal Chemistry and Drug Discovery.

[18]  Andreas Grassauer,et al.  Antiviral Effects of Pyrrolidine Dithiocarbamate on Human Rhinoviruses , 2002, Journal of Virology.

[19]  Peter Gedeck,et al.  QSAR - How Good Is It in Practice? Comparison of Descriptor Sets on an Unbiased Cross Section of Corporate Data Sets , 2006, J. Chem. Inf. Model..

[20]  Anton J. Hopfinger,et al.  Application of Genetic Function Approximation to Quantitative Structure-Activity Relationships and Quantitative Structure-Property Relationships , 1994, J. Chem. Inf. Comput. Sci..

[21]  Corwin Hansch,et al.  Chemical Toxicity on HeLa Cells. , 2006, Current medicinal chemistry.

[22]  Jaroslaw Polanski,et al.  Receptor dependent multidimensional QSAR for modeling drug--receptor interactions. , 2009, Current medicinal chemistry.

[23]  D. Matthews,et al.  Conservation of Amino Acids in Human Rhinovirus 3C Protease Correlates with Broad-Spectrum Antiviral Activity of Rupintrivir, a Novel Human Rhinovirus 3C Protease Inhibitor , 2005, Antimicrobial Agents and Chemotherapy.

[24]  A. Doweyko,et al.  The hypothetical active site lattice. An approach to modelling active sites from data on inhibitor molecules. , 1988, Journal of medicinal chemistry.

[25]  H. Rotbart,et al.  Treatment of picornavirus infections. , 2002, Antiviral research.

[26]  Cinzia Conti,et al.  Synthesis and Anti-Rhinovirus Properties of Fluoro-Substituted Flavonoids , 2005, Antiviral chemistry & chemotherapy.

[27]  M. Hartmann.  Molecular mechanics. Von ULRICH BURKERT und NORMAN L. ALLINGER. ACS Monograph 177. Washington: American Chemical Society 1982. 430 S., US $ 77.95 , 1984 .

[28]  Sydney B. Newell.  Chemistry: An introduction , 1980 .

[29]  M. Sarvà,et al.  Synthesis of new 3-methylthio-5-aryl-4-isothiazolecarbonitriles with broad antiviral spectrum. , 2002, Antiviral research.

[30]  Eugene N. Muratov,et al.  Computer-aided Drug Design of Novel Anti-coxsackievirus B3 Nancy Agents by Means of Hit QSAR , 2009 .

[31]  J. Mallamo,et al.  Antirhinoviral activity of heterocyclic analogs of Win 54954. , 1992, Journal of medicinal chemistry.

[32]  J. Leszczynski,et al.  The effect of nitroaromatics' composition on their toxicity in vivo: novel, efficient non-additive 1D QSAR analysis. , 2008, Chemosphere.

[33]  W. Richards,et al.  Self-organizing molecular field analysis: a tool for structure-activity studies. , 1999, Journal of medicinal chemistry.

[34]  Victor Kuzmin,et al.  Application of Random Forest Approach to QSAR Prediction of Aquatic Toxicity , 2009, J. Chem. Inf. Model..

[35]  A. Patick,et al.  Rhinovirus chemotherapy , 2006, Antiviral Research.

[36]  Paul Geladi,et al.  Interactive variable selection (IVS) for PLS. Part 1: Theory and algorithms , 1994 .

[37]  Anatoly G. Artemenko,et al.  QSAR Studies On [(Biphenyloxy)propyl]isoxazole Derivatives With Anti-rhinovirus 2 Activity , 2007 .

[38]  Markus A Lill,et al.  Multi-dimensional QSAR in drug discovery. , 2007, Drug discovery today.

[39]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[40]  A. Tropsha,et al.  Development of quantitative structure-binding affinity relationship models based on novel geometrical chemical descriptors of the protein-ligand interfaces. , 2006, Journal of medicinal chemistry.

[41]  Yvonne C. Martin,et al.  The Information Content of 2D and 3D Structural Descriptors Relevant to Ligand-Receptor Binding , 1997, J. Chem. Inf. Comput. Sci..

[42]  M A McKinlay,et al.  Synthesis and structure-activity studies of some disubstituted phenylisoxazoles against human picornavirus. , 1989, Journal of medicinal chemistry.

[43]  G. Klebe,et al.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.

[44]  Luc Morin-Allory,et al.  2D QSAR Consensus Prediction for High-Throughput Virtual Screening. An Application to COX-2 Inhibition Modeling and Screening of the NCI Database , 2004, J. Chem. Inf. Model..

[45]  Victor Kuzmin,et al.  Hierarchical QSAR technology based on the Simplex representation of molecular structure , 2008, J. Comput. Aided Mol. Des..

[46]  Alexander Golbraikh,et al.  Predictive QSAR modeling workflow, model applicability domains, and virtual screening. , 2007, Current pharmaceutical design.

[47]  Lemont B. Kier,et al.  Electrotopological State Indices for Atom Types: A Novel Combination of Electronic, Topological, and Valence State Information , 1995, J. Chem. Inf. Comput. Sci..

[48]  Bo Liu,et al.  Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics. , 2002, Journal of medicinal chemistry.

[49]  Paul Harten,et al.  A Hierarchical Clustering Methodology for the Estimation of Toxicity , 2008, Toxicology mechanisms and methods.

[50]  R. Venkataraghavan,et al.  Atom pairs as molecular features in structure-activity studies: definition and applications , 1985, J. Chem. Inf. Comput. Sci..

[51]  Roberto Todeschini,et al.  Handbook of Molecular Descriptors , 2002 .

[52]  Darko Butina,et al.  Modeling Aqueous Solubility , 2003, J. Chem. Inf. Comput. Sci..

[53]  Rick Mullin.  Drug Development Costs About $1.7 Billion , 2003 .

[54]  Jerzy Leszczynski,et al.  Consensus QSAR Modeling of Phosphor‐Containing Chiral AChE Inhibitors , 2009 .

[55]  Igor V. Tetko,et al.  Lattice Model for QSAR Studies , 2000 .

[56]  Manuela Pavan,et al.  New QSAR Modelling Approach Based on Ranking Models by Genetic Algorithms - Variable Subset Selection (GA-VSS) , 2006 .

[57]  Victor E. Kuz’min.  Antiviral Activity of Tetrahydro-2(1H)-Pyrimidinones and Related Compounds: Classification SAR Study , 2009 .

[58]  V V Poroikov,et al.  A new approach to QSAR modelling of acute toxicity , 2007, SAR and QSAR in environmental research.

[59]  Patric R. J. Östergård,et al.  A fast algorithm for the maximum clique problem , 2002, Discret. Appl. Math..

[60]  S. Wold,et al.  A PLS kernel algorithm for data sets with many variables and fewer objects. Part 1: Theory and algorithm , 1994 .

[61]  Anatoly G. Artemenko,et al.  Hit QSAR Analysis of Anti-Coxsackievirus B3 Activity of [(Biphenyloxy)Propyl]Isoxazole Derivatives , 2008 .

[62]  E. Muratov,et al.  Quantitative structure-activity relationship studies of [(biphenyloxy)propyl]isoxazole derivatives. Inhibitors of human rhinovirus 2 replication. , 2007, Journal of medicinal chemistry.

[63]  Eugene N Muratov,et al.  The analysis of structure-anticancer and antiviral activity relationships for macrocyclic pyridinophanes and their analogues on the basis of 4D QSAR models (simplex representation of molecular structure). , 2002, Acta biochimica Polonica.

[64]  Alexander Tropsha,et al.  Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. , 2010, Chemical research in toxicology.

[65]  Alexandre Varnek,et al.  Substructural fragments: an universal language to encode reactions, molecular and supramolecular structures , 2005, J. Comput. Aided Mol. Des..

[66]  Igor V. Tetko,et al.  Combinatorial QSAR Modeling of Chemical Toxicants Tested against Tetrahymena pyriformis , 2008, J. Chem. Inf. Model..

[67]  Polina V. Oliferenko,et al.  Nitrobenzene toxicity: QSAR correlations and mechanistic interpretations , 2003 .

[68]  A. Tropsha,et al.  Beware of q2! , 2002, Journal of molecular graphics & modelling.

[69]  Hugo Kubinyi,et al.  Quantitative structure-activity relationships (QSAR) and molecular modelling in cancer research , 2005, Journal of Cancer Research and Clinical Oncology.

[70]  Hugo Kubinyi,et al.  Evolutionary variable selection in regression and PLS analyses , 1996 .

[71]  E. Muratov,et al.  Investigation of anticancer activity of macrocyclic Schiff bases by means of 4D-QSAR based on simplex representation of molecular structure , 2005, SAR and QSAR in environmental research.

[72]  Anatoly G. Artemenko,et al.  QSAR Analysis of Cytotoxicity in HeLa Cells , 2008 .

[73]  Eugene N. Muratov,et al.  Molecular Design of Active Antiherpetic Compounds Using Hierarchic QSAR Technology , 2007 .

[74]  Anatoly G. Artemenko,et al.  QSAR Analysis of Anti-Coxsackievirus B3 Nancy Activity of 2-Amino-3-Nitropyrazole[1,5-α]Pyrimidines by Means of Simplex Approach , 2007 .

[75]  Alexander Golbraikh,et al.  Combinatorial QSAR of Ambergris Fragrance Compounds , 2004, J. Chem. Inf. Model..

[76]  Alexander Tropsha,et al.  Trust, But Verify: On the Importance of Chemical Structure Curation in Cheminformatics and QSAR Modeling Research , 2010, J. Chem. Inf. Model..

[77]  Michaela Schmidtke,et al.  QSAR analysis of [(biphenyloxy)propyl]isoxazoles: agents against coxsackievirus B3. , 2011, Future medicinal chemistry.

[78]  Klaus-Robert Müller,et al.  Benchmark Data Set for in Silico Prediction of Ames Mutagenicity , 2009, J. Chem. Inf. Model..

[79]  E. Muratov,et al.  Artificial ribonucleases: Quantitative analysis of the structure-activity relationship and a new insight into the strategy of design of highly efficient RNase mimetics , 2008, Russian Journal of Bioorganic Chemistry.

[80]  Gareth Thomas,et al.  Medicinal Chemistry: An Introduction , 2000 .

[81]  A S Galabov,et al.  Antiviral activity of tetrahydro-2(1H)-pyrimidinones and related compounds. , 1984, Arzneimittel-Forschung.

[82]  P Wutzler,et al.  Identification of individual structural fragments of N,N'-(bis-5-nitropyrimidyl)dispirotripiperazine derivatives for cytotoxicity and antiherpetic activity allows the prediction of new highly active compounds. , 2007, The Journal of antimicrobial chemotherapy.

[83]  Anatoly G. Artemenko,et al.  QSAR Analysis of Influence of Artifical Ribonucleases Structure on their Anti-influenza Activity , 2008 .

[84]  Alexander Golbraikh,et al.  A Novel Automated Lazy Learning QSAR (ALL-QSAR) Approach: Method Development, Applications, and Virtual Screening of Chemical Databases Using Validated ALL-QSAR Models , 2006, J. Chem. Inf. Model..